Observational studyMedicine2025
Rituximab for refractory minimal change disease: Long-term outcomes in the remission maintenance phase.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minimal change disease (MCD) has a high recurrence rate, with refractory MCD frequently requiring long-term corticosteroid therapy or combination regimens with other immunosuppressive agents. Rituximab (RTX) has been confirmed to be an effective treatment for refractory MCD. However, its role in remission maintenance remains uncertain. This study aimed to assess RTX dosing strategies, infusion intervals, and relapse predictors during the remission maintenance phase of refractory MCD. We conducted a retrospective analysis of 14 patients with refractory MCD who had achieved complete remission with corticosteroids or conventional immunosuppressants and subsequently received RTX during the maintenance phase. The mean follow-up period was 31.1 ± 9.6 months. RTX was administered intravenously at a dose of 375 mg/m2 body surface area or 1000 mg every infusion. Based on their laboratory results, RTX therapy was administered in the patients intermittently. Patients who experienced recurrence were withdrawn from the study for further observation and management. Patients were treated with RTX at 375 mg/m2 body surface area or 1000 mg with each infusion in the remission maintenance phase. The mean intervals from the first to second and from the second to third infusions were 7.9 ± 2.1 months and 11.8 ± 2.8 months, respectively. Eight patients remained in remission and 6 patients experienced a relapse. Steroids or immunosuppressants were discontinued in 12 patients, while a dose reduction was achieved in 2 others. The relapse frequency significantly decreased from 1.87 (0.43-2.69) to 0 (0.00-1.33; P < .05). Recurrence was negatively associated with additional annual RTX therapy (P < .05). Serious side effects were not found. RTX is associated with reduced relapse frequency and earlier discontinuation of corticosteroids and immunosuppressants in refractory MCD patients during remission maintenance. Additional annual RTX administration represents an effective strategy for decreasing disease recurrence. Our findings suggest potential benefit of early administration. While findings are promising, larger controlled studies are necessary to establish optimal dosing intervals and long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.